Cancer screening in myositis: the path has always been unclear and inconsistent Workable consensus recommendations @Dr_Alex_Oldroyd risk stratification but still extensive investigation burden for most now need to look at effectiveness including cost ABST0002 #ACR22 @RheumNow https://t.co/322qnGjB9K